Business Context and Reporting Period
This Form 8-K was filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on May 11, 2018, with the report signed on May 16, 2018. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Private Placement of Units (Common Stock and Warrants).
- Total Aggregate Purchase Price: Approximately $75 million.
- Units Sold: 33,003,296 Units.
- Components per Unit:
- 1 Share of Common Stock (Par value $0.00000002).
- 1 Warrant to purchase 0.5 shares of Common Stock.
- Per Unit Purchase Price: $2.2725.
- Warrant Details:
- Total Warrant Shares: Up to 16,501,645.
- Exercise Price: $2.54 per share (subject to adjustment).
- Exercise Period: Immediately exercisable through May 16, 2023.
- Exercise Method: Cash or cashless.
- Closing Date: May 16, 2018.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement and a Registration Rights Agreement.
- Securities Purchase Agreement: Established the terms for the sale of Units to identified Purchasers. The agreement includes customary representations, warranties, and indemnification obligations.
- Registration Rights Agreement: The Company agreed to file a registration statement on Form S-3 to register the resale of the securities. The Company must use commercially reasonable efforts to have the statement declared effective as soon as practicable.
- Liquidated Damages: The Registration Rights Agreement provides for payment of liquidated damages to Purchasers under certain circumstances if the Registration Statement is not declared effective.
- Regulatory Status: Securities were issued under the private placement exemption (Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D) and are not registered under the Securities Act.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operational performance.
- Risks and Contingencies:
- Investors are cautioned not to rely on representations and warranties in the Purchase Agreement as characterizations of the actual state of facts, as they are subject to qualifications and confidential disclosures.
- Warrant exercise is subject to beneficial ownership limitations (blackout provisions) to prevent holders from exceeding specified ownership percentages.
- Failure to obtain effectiveness of the Registration Statement may trigger liquidated damages.
- Unusual Items: The filing notes that the Company is not an emerging growth company.
Important Facts for Investor Verification
- Verify the identity of the "Purchasers" listed in Exhibit A of the Securities Purchase Agreement to understand the investor base.
- Confirm the status of the Form S-3 Registration Statement filing and its effectiveness date.
- Review the specific beneficial ownership limitations in the Warrants to understand potential restrictions on future share issuance.
- Check for any subsequent filings regarding the use of the $75 million proceeds raised.
- Note that the filing text does not provide current revenue, profit, cash flow, or debt levels; these metrics are not disclosed in this specific 8-K.